Involvement of P-glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone

Journal of Pharmacy and Pharmacology

Volumn 57, Issue 11, 2005, Pages 1421-1425

  Pawlik, A ^a   Baskiewicz Masiuk M ^a   Machalinski B ^a   Safranow, K ^a   Gawronska Szklarz B ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; GLYCOPROTEIN P; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL; ANTIINFLAMMATORY AGENT; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CYTOKINES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON TYPE II; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; METHOTREXATE; P-GLYCOPROTEIN; PHYTOHEMAGGLUTININS; TUMOR NECROSIS FACTOR-ALPHA; VERAPAMIL;

EID: 34548100791     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.57.11.0007     Document Type: Article

References (21)

1. Auphan, N., Didonato, J. A., Helmberg, A., Rosette, C., Karin, M. (1997) Immunoregulatory genes and immunosuppression by glucocorticoids. Arch. Toxicol. Suppl. 19: 87-95
2. Bourgeois, S. D., Gruol, J., Newby, R. F., Rajah, F. M., (1993) Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol. Endocrinol. 7: 840-851
3. Constantin, A., Loubet-Lescoulie, P., Lambert, N., Yassine-Diab, B., Abbal, M., Mazieres, B., de Preval, C., Cantagrel, A. (1998) Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 41: 48-57
4. Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38: 1277-1287
5. de Graaf, D., Sharma, R. C., Mechetner, E. B., Schimke, R. T., Roninson, I. B. (1996) P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl Acad. Sci. USA 93: 1238-1242
6. Drach, J., Gsur, A., Hamilton, G., Zhao, S., Angerler, J., Fiegl, M., Zojer, N., Raderer, M., Haberl, I., Andreeff, M., Huber, H. (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88: 1747-1754
7. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesmann, M. M., Pastan, I. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl Acad. Sci. USA 84: 265-269
8. Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., Revillard, J. P. (1998) Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest. 102: 322-328
9. Gollapudi, S., Kim, C., Gupta, S. (2000) P-glycoprotein (encoded by multidrug resistance genes) is not required for interleukin-2 secretion in mice and humans. Genes Immun. 1: 371-379
10. Klimecki, W. T., Futscher, B. W., Grogan, T. M., Dalton, W. S. (1994) P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83: 2451-2458
11. Lum, B. L., Gosland, M. P. (1995) MDR expression in normal tissues:pharmacological implications for the clinical use of the P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am. 9: 319-336
12. Nelson, E. J., Hinkle, P. M. (1992) Characterization of multidrug-resistant pituitary tumor cells. Endocrinology 130: 3246-3256
13. Neurath, M. F., Hildner, K., Becker, C., Schlaak, J. F., Barbulescu, K., Germann, T., Schmitt, E., Schirmacher, P., Haralambous, S., Pasparakis, M., Meyer Zum Buschenfelde, K. H., Kollias, G., Marker-Hermann, E. (1999) Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression Clin. Exp. Immunol. 115: 42-55
14. Norris, M. D., De Graaf, D., Haber, M., Kavallaris, M., Madafiglio, J., Gilbert, J., Kwan, E., Stewart, B. W., Mechetner, E. B., Gudkov, A. V., Roninson, I. B. (1996) Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int. J. Cancer 65: 613-619
15. Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I., Gawronska-Szklarz, B. (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharm. Ther. 42: 496-503
16. Pawlik, A., Baskiewicz-Masiuk, M., Machalinski, B., Gawronska-Szklarz, B. (2005) Involvement of P-gp in the process of apoptosis in peripheral blood mononuclear cells. Int. Immunopharmacol. 5: 821-828
17. Raghu, G., Park, S. W., Roninson, I. B., Mechetner, E. B. (1996) Monoclonal antibodies against P-glycoprotein an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp. Hematol. 24: 1258-1264
18. Saitoh, H., Hatakeyama, M., Eguchi, O., Oda, M., Takada, M. (1998) Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 87: 73-75
19. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., Borst, P. (1995) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96: 1698-1705
20. Shi, T., Wrin, J., Reeder, J., Liu, D., Ring, D. B. (1995) High-affinity monoclonal antibodies against P-glycoprotein. Clin. Immunol. Immunopathol. 76: 44-51
21. Varma, M. V., Ashokraj, Y., Dey, C. S., Panchagnula, R. (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48: 347-359